EBX 102 02
Alternative Names: EBX-102-02Latest Information Update: 13 Jul 2026
At a glance
- Originator EnteroBiotix
- Class Anti-inflammatories; Bacteria; Irritable bowel syndrome therapies
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Irritable bowel syndrome; Transplant rejection
Most Recent Events
- 08 May 2026 EnteroBiotix initiates enrolment in a phase II trial for Irritable bowel syndrome in United Kingdom (PO) (ISRCTN15681288)
- 05 May 2026 Updated efficacy data from the phase II TrIuMPH trial for Irritable bowel syndrome presented at the Digestive Disease Week 2026 (DDW 2026)
- 29 Apr 2026 EnteroBiotix plans a phase IIb RISE trial for Irritable bowel syndrome (PO), in United Kingdom, in second half of 2026